Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials

Shelley, M. D., Kumar, S., Coles, Bernadette Mary ORCID: https://orcid.org/0000-0003-0695-2865, Wilt, T., Staffurth, John Nicholas ORCID: https://orcid.org/0000-0002-7834-3172 and Mason, Malcolm David ORCID: https://orcid.org/0000-0003-1505-2869 2009. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treatment Reviews 35 (7) , pp. 540-546. 10.1016/j.ctrv.2009.05.001

Full text not available from this repository.

Abstract

Background Adjuvant hormone therapy (AHT) following radiotherapy or surgery is a treatment option frequently offered to men with localised or locally advanced prostate cancer. We performed a systematic review of published randomised trials to assess the effectiveness of AHT. Methods We searched MEDLINE, EMBASE, the Cochrane library, SCI, LILACS and SIGLE for randomised trials comparing AHT plus primary therapy (radiotherapy or prostatectomy) with primary therapy alone. Data on study design, participants interventions and outcomes were extracted from relevant studies and where possible pooled for meta-analysis. Findings AHT following radiotherapy improved overall survival (at 5 years OR fixed effect model 1.29, 95% CI 1.07–1.56, p = 0.007), disease-specific survival (OR 2.10, 95% CI 1.53–2.88, p < 0.00001) and disease-free survival (OR 1.91, 95% CI 1.16–2.23, p < 0.00001). A random effect model favoured adjuvant hormone therapy but did not reach significance. After prostatectomy, there was no significant overall survival advantage with AHT, although one study reported a significant improvement in disease-specific survival (HR 4.09, p = 0.0004). Disease-free survival was also better with AHT (OR 3.73, 95% CI 2.30–6.03, p < 0.00001). AHT-induced toxicities included gynaecomastia, impotence, gastrointestinal and haematological. Conclusions There are significant clinical benefits associated with the use of AHT for early prostate cancer. Patients should make an informed decision to accept AHT based on its effectiveness and side-effects.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Academic & Student Support Service Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	adjuvant hormone therapy, radiotherapy, prostatectomy, prostate cancer, systematic review, meta-analysis
Publisher:	Elsevier
ISSN:	0305-7372
Last Modified:	22 Jul 2024 13:48
URI:	https://orca.cardiff.ac.uk/id/eprint/24505

Citation Data

Cited 37 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item